Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.29
PRGO's Cash to Debt is ranked higher than
54% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. PRGO: 0.29 )
PRGO' s 10-Year Cash to Debt Range
Min: 0   Max: 18.37
Current: 0.29

0
18.37
Equity to Asset 0.63
PRGO's Equity to Asset is ranked higher than
72% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. PRGO: 0.63 )
PRGO' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.75
Current: 0.63

0.34
0.75
F-Score: 4
Z-Score: 3.36
M-Score: -2.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 12.86
PRGO's Operating margin (%) is ranked higher than
81% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. PRGO: 12.86 )
PRGO' s 10-Year Operating margin (%) Range
Min: -32.27   Max: 19.18
Current: 12.86

-32.27
19.18
Net-margin (%) 4.67
PRGO's Net-margin (%) is ranked higher than
70% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. PRGO: 4.67 )
PRGO' s 10-Year Net-margin (%) Range
Min: -34.47   Max: 12.66
Current: 4.67

-34.47
12.66
ROE (%) 2.58
PRGO's ROE (%) is ranked higher than
65% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. PRGO: 2.58 )
PRGO' s 10-Year ROE (%) Range
Min: -62.64   Max: 25.88
Current: 2.58

-62.64
25.88
ROA (%) 1.57
PRGO's ROA (%) is ranked higher than
67% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. PRGO: 1.57 )
PRGO' s 10-Year ROA (%) Range
Min: -28.65   Max: 11.48
Current: 1.57

-28.65
11.48
ROC (Joel Greenblatt) (%) 33.03
PRGO's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. PRGO: 33.03 )
PRGO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -70.75   Max: 53.06
Current: 33.03

-70.75
53.06
Revenue Growth (3Y)(%) 6.00
PRGO's Revenue Growth (3Y)(%) is ranked higher than
73% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. PRGO: 6.00 )
PRGO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -5.5   Max: 17.5
Current: 6

-5.5
17.5
EBITDA Growth (3Y)(%) 8.10
PRGO's EBITDA Growth (3Y)(%) is ranked higher than
74% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. PRGO: 8.10 )
PRGO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -25.1   Max: 40.1
Current: 8.1

-25.1
40.1
EPS Growth (3Y)(%) -21.40
PRGO's EPS Growth (3Y)(%) is ranked higher than
60% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. PRGO: -21.40 )
PRGO' s 10-Year EPS Growth (3Y)(%) Range
Min: -66.2   Max: 210.7
Current: -21.4

-66.2
210.7
» PRGO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

PRGO Guru Trades in Q4 2013

Eric Mindich 106,904 sh (New)
Robert Bruce 9,926 sh (New)
Louis Moore Bacon 2,131 sh (New)
David Rolfe 1,459,279 sh (+4.7%)
Jim Simons 471,810 sh (+4.09%)
Jeremy Grantham Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Mariko Gordon 29,300 sh (-0.59%)
Ruane Cunniff 1,763,823 sh (-0.97%)
John Keeley 34,289 sh (-1.63%)
Paul Tudor Jones 3,600 sh (-2.7%)
Ken Fisher 499,419 sh (-14.45%)
Ron Baron 126,830 sh (-37.61%)
» More
Q1 2014

PRGO Guru Trades in Q1 2014

Steven Cohen 72,588 sh (New)
George Soros 85,000 sh (New)
Ray Dalio 62,322 sh (New)
Jeremy Grantham 17,900 sh (New)
David Rolfe 1,494,779 sh (+2.43%)
Robert Bruce 9,926 sh (unchged)
Vanguard Health Care Fund 3,094,152 sh (unchged)
Eric Mindich Sold Out
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Ruane Cunniff 1,718,939 sh (-2.54%)
Mariko Gordon 28,520 sh (-2.66%)
Ken Fisher 483,860 sh (-3.12%)
John Keeley 28,741 sh (-16.18%)
Ron Baron 77,865 sh (-38.61%)
Paul Tudor Jones 1,800 sh (-50%)
» More
Q2 2014

PRGO Guru Trades in Q2 2014

Alan Fournier 472,300 sh (New)
Paul Tudor Jones 150,000 sh (+8233.33%)
David Rolfe 1,742,399 sh (+16.57%)
John Keeley 30,593 sh (+6.44%)
Vanguard Health Care Fund 3,210,552 sh (+3.76%)
Ron Baron 78,373 sh (+0.65%)
Ken Fisher 486,226 sh (+0.49%)
Steven Cohen 15,000 sh (unchged)
Robert Bruce 9,926 sh (unchged)
George Soros Sold Out
Jeremy Grantham Sold Out
Ray Dalio Sold Out
Mariko Gordon 28,494 sh (-0.09%)
Ruane Cunniff 1,717,063 sh (-0.11%)
» More
Q3 2014

PRGO Guru Trades in Q3 2014

Joel Greenblatt 1,665 sh (New)
Jim Simons 199,308 sh (New)
Steven Cohen 77,300 sh (+415.33%)
Alan Fournier 932,457 sh (+97.43%)
Vanguard Health Care Fund 3,305,652 sh (+2.96%)
David Rolfe 1,788,328 sh (+2.64%)
Ron Baron 79,307 sh (+1.19%)
Robert Bruce 9,926 sh (unchged)
Mariko Gordon 28,494 sh (unchged)
Ruane Cunniff 1,710,706 sh (-0.37%)
John Keeley 30,263 sh (-1.08%)
Ken Fisher 477,504 sh (-1.79%)
Paul Tudor Jones 135,204 sh (-9.86%)
» More
» Details

Insider Trades

Latest Guru Trades with PRGO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy$139 - $158.85 $ 168.1413%1665
George Soros 2014-06-30 Sold Out 0.13%$126.87 - $157.2 $ 168.1419%0
Ray Dalio 2014-06-30 Sold Out 0.08%$126.87 - $157.2 $ 168.1419%0
George Soros 2014-03-31 New Buy0.13%$145.74 - $167.6 $ 168.147%85000
Ray Dalio 2014-03-31 New Buy0.08%$145.74 - $167.6 $ 168.147%62322
Ron Baron 2014-03-31 Reduce -38.61%0.03%$145.74 - $167.6 $ 168.147%77865
Robert Bruce 2013-12-31 New Buy0.43%$125.11 - $156.88 $ 168.1416%9926
Ron Baron 2013-12-31 Reduce -37.61%0.04%$125.11 - $156.88 $ 168.1416%126830
George Soros 2013-12-31 Sold Out 0.03%$125.11 - $156.88 $ 168.1416%0
Ron Baron 2013-09-30 Reduce -36.19%0.07%$116.83 - $134.23 $ 168.1435%203294
George Soros 2013-09-30 New Buy0.03%$116.83 - $134.23 $ 168.1435%19000
Meridian Funds 2013-06-30 Add 72.42%0.92%$113.14 - $121.16 $ 168.1442%482100
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Perrigo Co PLC

David Rolfe Comments on Perrigo - Jan 27, 2014

During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth - having acquired six new businesses over the past 18 months (including Elan) - we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” is a multi-year trend that we expect will continue for the foreseeable future as consumers continue to become more value-conscious, yet more comfortable with store-brand quality that Perrigo helps engineer. 

 

From David Rolfe (Trades, Portfolio)’s Wedgewood Partners Fourth Quarter 2013 Commentary.

Check out David Rolfe latest stock trades

Meridian Funds Comments on Perrigo - Aug 28, 2013

Perrigo (PRGO) is a global manufacturer of over-the-counter (OTC) store brand and generic prescription pharmaceuticals, infant formulas, nutritional products and active pharma ingredients. The company is the dominant player in the OTC drug market with the largest distribution network and broadest range of product offerings. The OTC store brands have increased their market share by about 1-2% annually at the expense of national name product given their superior value proposition to both the consumer and retailers. Perrigo has numerous growth drivers over the next few years including the continued penetration of OTC store brands and introduction of new product categories. The stock sells at a reasonable valuation, in our opinion, given the company's strong management team, financial returns and long-term growth prospects.

From Meridian Funds's commentary for the quarter ended June 30, 2013.


Check out Meridian Funds latest stock trades

Baron Funds Comments on Perrigo - Feb 06, 2013

Shares of Perrigo Co. (PRGO), the largest manufacturer of store brand, over-thecounter pharmaceutical products, fell after quarterly revenues in its Nutritionals segment, which includes private label infant formula and vitamins, fell short of expectations. We believe that the shortfall was explained by a combination of short term factors, and we are optimistic that the company's infant formula revenues are poised for strong growth, particularly in China, where its points of distribution are increasing.We are also encouraged by Perrigo's recent accretive acquisition of Sergeant's Pet Care, through which the company entered the market for private-label pet medications.

From Baron Funds' fourth quarter letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about Perrigo Co PLC

David Rolfe Comments on Perrigo
During the quarter, Perrigo (PRGO) announced strong September quarter adjusted earnings growth of 20%.  We say “adjusted” because the Company incurred what we believe are non-recurring charges related to the recent purchase of Elan Corporation, which is a branded-drug company domiciled in Ireland.  Upon the closing of this purchase, Perrigo has “re-domiciled” itself in Ireland, with an effective tax rate meaningfully below what they were subjected to in the U.S.  Given that the Company actively pursues a strategy of inorganic growth as much as it pursues organic growth - having acquired six new businesses over the past 18 months (including Elan) - we expect that this new tax structure should make future acquisitions, particularly those U.S. based businesses, much more attractive.  Further, Perrigo’s core business, which includes private-label over-the-counter (OTC) pharmaceuticals and infant formula, drove much of the year-over-year growth.  The Company’s unrivaled scale in manufacturing and marketing of store-branded offerings continues to enable retailers to mimic the value proposition of OTC pharmaceuticals and infant formula.  This “store-brand conversion” Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 140.90
PRGO's P/E(ttm) is ranked higher than
68% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.60 vs. PRGO: 140.90 )
PRGO' s 10-Year P/E(ttm) Range
Min: 13.36   Max: 140.94
Current: 140.9

13.36
140.94
P/B 2.58
PRGO's P/B is ranked higher than
79% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. PRGO: 2.58 )
PRGO' s 10-Year P/B Range
Min: 2.01   Max: 5.96
Current: 2.58

2.01
5.96
P/S 5.17
PRGO's P/S is ranked higher than
68% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. PRGO: 5.17 )
PRGO' s 10-Year P/S Range
Min: 0.95   Max: 5.09
Current: 5.17

0.95
5.09
PFCF 34.31
PRGO's PFCF is ranked higher than
89% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 34.31 )
PRGO' s 10-Year PFCF Range
Min: 10.63   Max: 86.68
Current: 34.31

10.63
86.68
EV-to-EBIT 47.31
PRGO's EV-to-EBIT is ranked higher than
73% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. PRGO: 47.31 )
PRGO' s 10-Year EV-to-EBIT Range
Min: -6.7   Max: 47.4
Current: 47.31

-6.7
47.4
PEG 8.62
PRGO's PEG is ranked higher than
83% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 8.62 )
PRGO' s 10-Year PEG Range
Min: 0.67   Max: 8.13
Current: 8.62

0.67
8.13
Shiller P/E 52.43
PRGO's Shiller P/E is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. PRGO: 52.43 )
PRGO' s 10-Year Shiller P/E Range
Min: 25   Max: 3968
Current: 52.43

25
3968
Current Ratio 2.59
PRGO's Current Ratio is ranked higher than
73% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. PRGO: 2.59 )
PRGO' s 10-Year Current Ratio Range
Min: 1.52   Max: 3.18
Current: 2.59

1.52
3.18
Quick Ratio 1.94
PRGO's Quick Ratio is ranked higher than
73% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. PRGO: 1.94 )
PRGO' s 10-Year Quick Ratio Range
Min: 0.89   Max: 2.87
Current: 1.94

0.89
2.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.25
PRGO's Dividend Yield is ranked lower than
89% of the 519 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. PRGO: 0.25 )
PRGO' s 10-Year Dividend Yield Range
Min: 0.22   Max: 1.23
Current: 0.25

0.22
1.23
Dividend Payout 0.27
PRGO's Dividend Payout is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 0.27 )
PRGO' s 10-Year Dividend Payout Range
Min: 0.07   Max: 0.42
Current: 0.27

0.07
0.42
Dividend growth (3y) 12.60
PRGO's Dividend growth (3y) is ranked higher than
87% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. PRGO: 12.60 )
PRGO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 49.8
Current: 12.6

0
49.8
Yield on cost (5-Year) 0.55
PRGO's Yield on cost (5-Year) is ranked lower than
80% of the 528 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.47 vs. PRGO: 0.55 )
PRGO' s 10-Year Yield on cost (5-Year) Range
Min: 0.4   Max: 2.24
Current: 0.55

0.4
2.24
Share Buyback Rate -7.30
PRGO's Share Buyback Rate is ranked higher than
64% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -1.30 vs. PRGO: -7.30 )
PRGO' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -9.8
Current: -7.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.80
PRGO's Price/DCF (Projected) is ranked higher than
89% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. PRGO: 1.80 )
PRGO' s 10-Year Price/DCF (Projected) Range
Min: 0.98   Max: 2.42
Current: 1.8

0.98
2.42
Price/Median PS Value 2.63
PRGO's Price/Median PS Value is ranked higher than
57% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. PRGO: 2.63 )
PRGO' s 10-Year Price/Median PS Value Range
Min: 0.28   Max: 2.34
Current: 2.63

0.28
2.34
Price/Peter Lynch Fair Value 8.13
PRGO's Price/Peter Lynch Fair Value is ranked higher than
87% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. PRGO: 8.13 )
PRGO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.76   Max: 7.24
Current: 8.13

0.76
7.24
Earnings Yield (Greenblatt) 2.10
PRGO's Earnings Yield (Greenblatt) is ranked higher than
73% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PRGO: 2.10 )
PRGO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.1   Max: 9.8
Current: 2.1

2.1
9.8
Forward Rate of Return (Yacktman) 19.71
PRGO's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 496 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.85 vs. PRGO: 19.71 )
PRGO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.8   Max: 36.4
Current: 19.71

1.8
36.4

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 4,673 5,681 5,733
EPS($) 7.38 8.54 9.53
EPS without NRI($) 7.38 8.54 9.53

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PIG.Germany, PRGO.Israel,
Perrigo Co PLC was incorporated under the laws of Ireland on June 28, 2013. The Company develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients. The Company is a manufacturer of OTC healthcare products for the store brand market. The Company has five reportable segments, aligned primarily by type of product: Consumer Healthcare, Nutritionals, Rx Pharmaceuticals, API, and Specialty Sciences. The Consumer Healthcare segment is the store brand manufacturer of OTC pharmaceutical products. Its product categories include analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation and animal health; secondary product categories include feminine hygiene, diabetes care and dermatological care. The Nutritionals segment develops, manufactures, markets and distributes store brand infant and toddler formula products, infant and toddler foods, and vitamin, mineral and dietary supplement products to retailers, distributors and consumers primarily in the U.S., Canada, Mexico and China. The Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of generic prescription drugs primarily for the U.S. market. it encompasses an array of topical dosage forms such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions and powders. The Company develops, manufactures, and markets API used worldwide by the generic drug industry and branded pharmaceutical companies. Certain of these ingredients are used in its own pharmaceutical products. The manufacturing of these API occurs primarily in Israel. As a result of the Elan acquisition on December 18, 2013, the Company expanded its operating segments to include the Specialty Sciences segment, which is comprised primarily of assets focused on the treatment of Multiple Sclerosis (Tysabri). Its competitors in the U.S. Consumer Healthcare market are Dr. Reddy's Laboratories, Ltd., Actavis Inc., Ranbaxy Inc., PL Developments, Nipro Corporation, and LNK International, Inc. Abbott Laboratories, Mead Johnson Nutrition Co., Nestle S.A. (Gerber) and Danone Baby Nutrition. Tysabri competes primarily with Avonex, marketed by Biogen Idec; Betaseron, marketed by Berlex (an affiliate of Bayer Schering Pharma AG) in the U.S. The Company is subject to various environmental laws and regulations.
» More Articles for PRGO

Headlines

Articles On GuruFocus.com
Fournier Finds Time for His Own Investments in the Third Quarter Dec 17 2014 
David Rolfe's Wedgewood Partners Q2 2014 Commentary Jul 15 2014 
David Rolfe Comments on Perrigo Jan 27 2014 
Weekly Insider Sells Highlight: ROC, PRGO, JCI, TEL, DISH Dec 16 2013 
Weekly CFO Sells Highlight: FleetCor Technologies Inc., Facebook Inc., Perrigo Company, WellPoint In Dec 15 2013 
Three Companies Gain in Bargain Portfolio Sep 26 2013 
Meridian Funds Comments on Perrigo Aug 28 2013 
Meridian Funds' Second Quarter 2013 Commentary Aug 28 2013 
The Truth About the Impact of Dividend Reinvesting Apr 10 2013 
Baron Funds Comments on Perrigo Feb 06 2013 

More From Other Websites
Stocks Off Highs But Stay Positive; Nike Drags Dow Dec 19 2014
Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Senior Notes Dec 02 2014
Perrigo Announces FDA Approval And Launch Of The Generic Version Of Pennsaid® 1.5% w/w Dec 02 2014
Perrigo Announces FDA Approval And Launch Of The Generic Version Of Pennsaid® 1.5% w/w Dec 02 2014
Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares Nov 26 2014
Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares Nov 26 2014
Perrigo Company plc Announces The Pricing Of Senior Notes Offering By Its Finance Subsidiary,... Nov 24 2014
Perrigo Company plc Announces The Pricing Of Senior Notes Offering By Its Finance Subsidiary,... Nov 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK